- Sections
- C - Chimiemétallurgie
- C07K - Peptides
- C07K 14/495 - Facteur de croissance transformant [TGF]
Détention brevets de la classe C07K 14/495
Brevets de cette classe: 626
Historique des publications depuis 10 ans
|
33
|
42
|
59
|
48
|
64
|
71
|
63
|
52
|
35
|
24
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Propriétaires principaux
| Proprétaire |
Total
|
Cette classe
|
|---|---|---|
| Acceleron Pharma Inc. | 341 |
23 |
| Cue Biopharma, Inc. | 205 |
20 |
| The Johns Hopkins University | 5875 |
15 |
| Biocon Limited | 221 |
13 |
| The Regents of the University of California | 20720 |
12 |
| Amgen Inc. | 4425 |
12 |
| NGM Biopharmaceuticals, Inc. | 169 |
12 |
| Scholar Rock, Inc. | 137 |
12 |
| University of Pittsburgh - Of the Commonwealth System of Higher Education | 3299 |
11 |
| Modernatx, Inc. | 1291 |
10 |
| io Biotech ApS | 78 |
9 |
| Mayo Foundation for Medical Education and Research | 3382 |
8 |
| In3bio Ltd. | 23 |
8 |
| Merck Patent GmbH | 5725 |
7 |
| National Research Council of Canada | 1551 |
7 |
| Notogen, Inc. | 7 |
7 |
| Immatics Biotechnologies GmbH | 1127 |
6 |
| University Health Network | 1061 |
6 |
| President and Fellows of Harvard College | 6091 |
5 |
| The Brigham and Women's Hospital, Inc. | 2282 |
5 |
| Autres propriétaires | 418 |